Objectives: The aim of this study is to examine the difference in the report of bodily pain experienced by patients who develop temporomandibular disorders (TMD) and by those who do not develop TMD over a 3-year observation period.
C
hronic pain is rarely present in a single body site. Three distinct patterns of pain distribution, namely, localized, regional, and widespread pain have been described. 1, 2 Heterogeneous pain symptoms are believed to share common neurophysiologic, psychologic, and behavioral mechanisms independent of specific differences in peripheral injury or disease. 3 Epidemiologic and clinical trials have also provided consistent evidence that regional and widespread chronic pain conditions should be considered as part of a ''continuum'' rather than distinct entities with distinct etiologies. 1, 4 Therefore, it is likely that there are some areas of shared risk exposure for all these pain conditions, implying that perhaps the face may be just 1 body region involved in a more widespread pain syndrome. 5 Various studies have since reported that facial pain is comorbid with widespread bodily pain. [6] [7] [8] [9] Temporomandibular disorders (TMD) is a collective term used to describe a number of related disorders involving the temporomandibular joints, masticatory muscles, and related structures. 10 Emerging evidence suggests a significant overlap between TMD states and pain conditions in other parts of the body, such as headaches, and neck, shoulder, and back pain. 2, 5, [11] [12] [13] Studies have also reported comorbidity between TMD and fibromyalgia, 14, 15 and that these 2 conditions seemed to have in common numerous clinical symptoms, such as generalized pain sensitivity. 4 Therefore, TMD may represent 1 manifestation of a more global pain sensitivity disorder. 4 In addition, cooccurring pain conditions in TMD patients may potentially influence the course of pain and associated psychologic disturbance and psychosocial dysfunction in these patients. 16, 17 Widespread pain has been cited as one of the risk factors for the persistence of TMD pain. 7 Patients with chronic TMD reported a greater number of body sites with pain than patients with remitted or recurrent TMD. 18 Furthermore, patients with frequent headaches or pain in other parts of the body had a 3-fold increase in risk of having TMD. 5 In women without dysfunctional TMD pain at baseline, widespread pain was a risk factor for the development of dysfunctional TMD pain. 19 Widespread pain was also highly associated with the risk of developing pain-related disability in female TMD patients. 19 Recent studies have shown that widespread pain is also a risk factor for the development or onset of TMD pain. Von Korff et al 20 reported that the presence of a pain condition at baseline was a more consistent predictor of subsequent risks of developing TMD than was the severity or chronicity of depressive symptoms. In a prospective study, LeResche et al 21 reported that the probability of developing TMD in early adolescence increased with the report of other pain conditions at baseline.
Associations reported by cross-sectional studies are not necessarily risk factors. They could be a consequence of having symptoms. 22 Longitudinal studies are more useful in examining the risk factors that are predictive of the onset of TMD. 13, 4 However, few longitudinal studies have used frequent follow ups in assessing the onset of pain conditions. The aim of this study was to examine the difference in the report of bodily pain experienced by participants who develop TMD and by those who do not develop TMD over a 3-year observation period. This will allow further understanding of the temporal relationship linking the development of various pain symptoms.
MATERIALS AND METHODS
This is a 3-year prospective study of 266 females aged 18 to 34 years initially free of TMD pain. participants were recruited by advertisements placed in local newspapers for a study designed to examine the relationship between pain sensitivity and the development of TMD. During the study visits (at baseline and at yearly intervals for 3 years), participants completed questionnaires that identified selfreported facial pain and TMD symptoms and underwent a physical examination of the head and neck conducted according to the Research Diagnostic Criteria (RDC) for TMD. 23 Individuals were excluded if they had a history of TMD or were diagnosed with TMD at the baseline examination. In addition to these study visits, online health surveys that included questions on facial pain and TMD symptoms were completed by the participants every 3 months over the 3-year period. After each survey, participants who responded positively to key questions about facial pain and TMD symptoms were recalled for a reexamination according to the RDC protocol. New cases of TMD were defined according to the RDC for Group I Myofascial Pain and/or Group III Arthralgia, both of which included reported pain and pain on palpation. 23 New cases were confirmed independently by 2 examiners.
All participants completed the Symptom Report Questionnaire (SRQ) (Fig. 1 ) at baseline and yearly intervals, and at the time they developed TMD (if applicable). The SRQ is a self-report instrument evaluating the extent and location of pain experienced in the earlier 6 months. Statistical analysis was carried out using repeated measures ANOVA.
RESULTS
Over the 3-year period, 16 participants (6%) developed TMD (based on the RDC for TMD 23 ). The rate at subsequent yearly follow-up was 69.9% (186 participants), 55.3% (147 participants), and 71.1% (189 participants) at the first, second, and third years, respectively.
Participants who developed TMD reported more headaches (P = 0.0089), muscle soreness or pain (P = 0.005), joint soreness or pain (P = 0.0012), back pain (P = 0.0001), chest pain (P = 0.0004), abdominal pain (P = 0.0021), and menstrual pain (P = 0.0036) than participants who did not develop TMD at both the baseline and the final visits (Fig. 2) .
Participants who developed TMD reported significantly more headaches (P = 0.0006), muscle soreness or pain (P = 0.0059), and other pains (P = 0.0188) when they were diagnosed with TMD compared with the baseline visit (Fig. 3) .
DISCUSSION
In this study, the 3-year cumulative incidence rate of TMD was 6%. This is similar to the former report of 3-year TMD onset rate of 6.5%. 20 Similarly, the onset rate of widespread pain in longitudinal studies involving participants with no initial pain was estimated to be between 2% to 10%, 24, 25 whereas the point prevalence of chronic widespread pain in a general population sample was about 11.2%. 26 The pain conditions examined by earlier studies included headaches, back pain, chest pain, joint pain, and abdominal pain. 20, 21 In this study we included muscle soreness or pain, pelvic pain, and menstrual pain. Menstrual pain reported by all patients in this study seemed to decrease over the observation period. One possible reason for this is that the experience of menstrual pain at baseline was considerably higher than the experience of the other pains, such as chest or pelvic pain. Therefore this may reflect a reduction in extent of menstrual pain experienced.
Von Korff et al 20 and LeResche et al 21 reported that widespread pain is a risk factor associated with the onset of TMD. In this study participants who developed TMD reported higher experience of joint, back, chest, and menstrual pain at baseline compared with those participants who did not develop TMD. Similarly, Korszun et al 15 reported that 67% of their cohort of TMD patients reported an onset of generalized pain symptoms before the onset of facial pain. 15 Bergman et al 27 also reported that the development of CWP from no chronic pain or chronic regional pain over a 3-year follow-up period was predicted by the number of painful regions at baseline.
Various other psychologic and social risk factors have also been identified as risk factors for the future development of CWP, including greater impairment of general health status, sleep disturbance, fatigue, and high psychologic distress. [28] [29] [30] [31] [32] [33] Paralleling the development of CWP, cooccurring physical symptoms, often referred to as somatization symptoms, function as potential significant prognosticators of the future clinical course in these patients. 34, 16 However, the most important clinical risk factor for chronic pain at a specific site seems to be pain. 35 Von Korff et al 20 reported that the presence of a pain condition at baseline was a more consistent predictor of subsequent risks of developing a new pain condition than was the severity of chronicity of depressive symptoms. In fact, the presence of 1 pain condition at baseline has been shown to be associated with a 4 times increased risk of developing TMD. 20 These findings are in agreement with various case-control studies which have suggested that it seems inappropriate to consider TMD in isolation. 5 Rather, regional and widespread chronic pain conditions represent ''overlapping'' conditions, and should be considered as part of a ''continuum'' than distinct entities with distinct etiologies.
14 That being said, there are also other risk factors unique to the development of TMD such as bruxism, history of facial trauma, and third-molar extraction, 5, 36 which may not present as significant risk factors for the development of pain in other areas of the body.
In this study the onset of TMD was accompanied by increases in headache, muscle, and other pains which were not reported in the group that did not develop TMD. Macfarlane et al reported that patients with headaches had a 3-fold increase in risk of having TMD. However, having pain in parts of the body other than the head also lead to a 3-fold increase in risk of having TMD. 5 Their data suggested that perhaps TMD and headache may share common etiologic factors, rather than that pain at 1 specific site altered the risk of developing pain at another specific site. On the contrary, Von Korff et al 20 studied the onset rates of back pain, headaches, chest pain, abdominal pain, and TMD, and found that the risk of onset of TMD was not significantly increased by the presence of any specific pain condition.
From a clinical perspective, the occurrence of TMD with widespread body pain may impact the management of such patients. Raphael et al 37 reported that TMD patients with widespread pain did not improve with occlusal splint therapy compared with those with just local pain. Future studies need to address the impact of widespread body pain on the prognosis of the various treatment modalities for TMD.
Our study had several strengths. The participation rate at subsequent follow-up was moderately high. We used reliable criterion-based examination (RDC for TMD) for the diagnosis of TMD for all patients. 23 Self-reported facial pain symptoms were obtained quarterly and this has been recommended to be a reasonably accurate recall period reducing response bias. 20, 32, 38 The longitudinal design used in this study allowed us to investigate the temporal relationship sequence linking the development of various pain symptoms, namely that widespread pain was reportedly present before the onset of TMD, and that the onset of TMD was accompanied by reportedly greater experience of widespread pain.
Several limitations of this study also deserve mention. Males were excluded in this study because the female sex has been reported to be a TMD risk factor. 39 Future studies need to investigate the relationship between widespread pain and the development of TMD in men. Our reliance on self-reported body pain symptoms based on a questionnaire (SRQ) is subject to recall bias. 40 Alternative methods of data collection, such as using daily diary, will avoid such bias. Moreover, although 3 monthly symptom report has been earlier recommended, 20, 32 our participants reported body pain symptoms experienced over the last 6 months. It has also been argued that the location and extent of chronic body pain are best determined by physical examination by a qualified practitioner. However, as pain is a subjective experience, the practitioner would still have to rely on self-report. Finally, this study examined only the pain experience associated with the onset of TMD. It is our intention to continue to track these patients to determine chronicity.
CONCLUSIONS
In this 3-year prospective study of 266 female participants aged 18 to 34 years initially free of TMD pain, 16 patients (6%) developed TMD. The development of TMD was accompanied by increases in headaches, muscle soreness or pain, and other pains that were not observed in the participants who did not develop TMD. Participants who developed TMD also report higher experience of joint, back, chest, and menstrual pain at baseline compared with those participants who did not develop TMD. 
